Repros Therapeutics jumps as Androxal meets endpoints

Repros Therapeutics (RPRX) soars 26% premarket.

Androxal topline results from ZA-302 (pivotal efficacy) and ZA-300 (six-month safety) show the secondary hypogonadism treatment met both primary endpoints and is generally well tolerated.

ZA-302 results are "almost identical" to the first pivotal efficacy study. (PR)

Expect an NDA in mid-2014.

RPRX says it expects to have "launch drug product available for an anticipated approval during 2015."

It's worth noting that back in July, BofA's Steve Byrne said peak 2022 sales could reach $450M.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs